Drug Trial Radar · NCT04603001
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
260
Planned (sponsor's estimate)
Start
Nov 19, 2020
Primary completion
Jul 3, 2023
Study completion May 2027
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Oct 26, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who may have received standard therapy
Conditions
- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
- Chronic Myelomonocytic Leukemia (CMML)
- Myeloproliferative Neoplasms (MPNs)
Interventions
LY3410738Drug
Oral LY3410738
VenetoclaxDrug
Oral venetoclax
AzacitidineDrug
Subcutaneous or intravenous azacitidine
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)Time frame: Up to 30 months
- To assess the activity of LY3410738 as measured by the overall response rate (ORR) per the Investigator assessmentTime frame: Up to 30 months
Locations
37 sites in 12 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
UCLA Medical Center
Los Angeles, California
University of California, Davis - Health Systems
Sacramento, California
H Lee Moffitt Cancer Center
Tampa, Florida
Northwestern University
Chicago, Illinois
University of Chicago Hospital
Chicago, Illinois
Massachusetts General Hospital
Boston, Massachusetts
Roswell Park Cancer Institute
Buffalo, New York
Memorial Sloan Kettering Cancer Center
New York, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Vanderbilt University Medical Center
Nashville, Tennessee
University of Texas MD Anderson Cancer Center
Houston, Texas
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
Cliniques universitaires Saint-Luc
Brussels, Belgium
BC Cancer Vancouver
Vancouver, British Columbia, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus)
Helsinki, Finland
Institut Paoli-Calmettes
Marseille, France
Hopital Saint Louis
Paris, France
Centre hospitalier universitaire de Haut Leveque
Pessac, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Institut Claudius Regaud
Toulouse, France
Medizinische Hochschule Hanover
Hanover, Lower Saxony, Germany
Rambam Medical Center
Haifa, Israel
National University Cancer Institute
Singapore, Singapore
Singapore General Hospital
Singapore, Singapore
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center
Seoul, Seoul-teukbyeolsi [Seoul], South Korea
Samsung Medical Center
Seoul, Seoul-teukbyeolsi [Seoul], South Korea
Clinico Y Provincial Barcelona
Barcelona, Spain
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
Hospital Universitario La Fe de Valencia
Valencia, Spain
China Medical University Hospital
Taichung, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.